BioProcess Insider - News BioProcess International

Trump’s ‘reckless’ drug pricing Executive Order threatens innovation, BIO

The US is doing more in the COVID-19 space than anywhere in the world due to the strength of its innovative ecosystem, says Michelle McMurry-Heath, head of trade group BIO. But such innovation is under threat due to “reckless” orders coming out of the White House. As part of an exclusive inte ...

Biopharma set for COVID-related single-use shortages, says survey
Biopharma faces delays obtaining single-use systems according to a survey that suggests disruption caused by the COVID-19 pandemic and increasing ...
Gardasil scale-up unaffected by COVID capacity chase, says Merck
Merck says bringing two plants online to feed demand for its blockbuster Gardasil remains a priority, despite industry’s unparalleled need for ...
Lilly turns to Amgen to up COVID-19 antibody production
Amgen will provide manufacturing capacity to support scale-up of monoclonal antibody candidates being developed by Eli Lilly against COVID-19. ...
Takeda opens MA manufacturing unit to support cell therapy R&D
The 24,000 square-foot cell therapy manufacturing facility will produce material through to Phase IIb trials, supporting Takeda’s cell therapy ...

Covering the whole development process for the global biotechnology industry

More From BioProcess Insider

Recent Tweets

Recent Tweets

Trending